Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients (OPTIMAL)

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:
NCT01348308
First received: May 2, 2011
Last updated: July 11, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)